Featured Story | By Annalee Armstrong Sanofi has big dreams for rilzabrutinib in diseases ranging from atopic dermatitis to asthma, but up first for the potential blockbuster is a phase 2 read out for the rare skin disease pemphigus vulgaris. read more |
| |
|---|
|
Top Stories By Ben Adams Bristol Myers Squibb’s hand was forced when it had to spin-off its blockbuster immunology med Otezla to Amgen, gained via its Celgene buyout, given that it had a similar oral deucravacitinib in the pipeline. read more By Annalee Armstrong U.S. officials have pulled the plug on funding a phase 3 trial for Inovio’s COVID-19 vaccine, telling the biotech that another vaccine is no longer needed as inoculations pick up around the country. read more Sponsored By: Catalent Cell & Gene Therapy Working with the right integrated partner can help ease increasingly common problems with scale, access to high-demand raw material, viral vector production and quality requirements. read more By Ben Adams In the middle of a new pandemic, it’s all too easy to forget older epidemics that have killed and continue to kill millions, with poor drug therapies and a weak vaccine. read more By Ben Adams Valneva has started a pivotal phase 3 test for its experimental COVID-19 vaccine in a head-to-head against AstraZeneca's conditionally approved pandemic shot Vaxzevria. read more By Angus Liu Bristol Myers Squibb and Roche led pharma's reputation score in Asia Pacific in this year's Global RepTrack 100 survey. Bharat Biotech and Serum Institute of India won government funding to boost production of COVID-19 vaccines, as Fosun Pharma preps for the potential China launch of BioNTech's mRNA shot. And more. read more By Fraiser Kansteiner Replimune has snagged Genentech oncology vet Sushil Patel to fill the CCO seat. Humanigen has opened up a CMO role and picked an AstraZeneca vet to fill it. Gossamer Bio's chief scientist will depart for pastures new. read more By Noah Higgins-Dunn Despite looming uncertainty tied to aducanumab's prospects at the FDA, Biogen says hundreds of clinical sites stand ready to administer its Alzheimer’s drug hopeful. Meanwhile, a look at the company's first-quarter revenues outlines just how critical the drug is for Biogen. read more Resources Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored By: August Bioservices How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond? Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: PerkinElmer Informatics Discover the benefits of a cloud-native ELN that delivers better performance, security, connectivity, total cost of ownership PLUS sub-second search results through even the largest data volumes. Sponsored by: PulsePoint Access this guide for the latest insights into how marketers can use data, technology, and personalized messaging to build vaccine confidence and drive successful immunization efforts. Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: TAC Roche has inked a $1.8 billion, all-cash deal for GenMark Diagnostics, to acquire its molecular tests designed to screen patient samples for multiple infections simultaneously. Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored By: Culture Biosciences Find out how upstream bioprocess scientists can use Culture Biosciences’ bioreactor system and real-time data visualizations to get faster insights and get their product to market more quickly. Sponsored By: BC Platforms Those wishing to unlock RWD’s true value must have access to a variety of data sources/types and the technological capabilities to use the data to uncover meaningful insights. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. | 
